Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

      May 26, 2023

      India as a Quad-led biomanufacturing hub

      May 25, 2023

      Manappuram Finance, Rossari Biotech shares trade ex-dividend today

      May 24, 2023

      Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

      May 23, 2023

      Israeli biotech phenom puts death knell on cancer

      May 22, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Israeli biotech phenom puts death knell on cancer
    Bio Technology

    Israeli biotech phenom puts death knell on cancer

    yourbiotechBy yourbiotechMay 22, 2023Updated:May 22, 2023No Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    At 44, Gal Markel is a biotech bulldozer. After a $95 million exit, the professor of immunology serves as the Deputy Director General of Beilinson Hospital and the Director of the Davidoff Cancer Center, and is also involved in five startups. Now he has raised around $33 million to establish the Samueli Institute, researching ways to help the immune system eradicate cancer cells

    “If you build it, they will come.” This is the philosophy that guides biotech entrepreneur Prof. Gal Markel, and it is not taken from a business administration book or from an inspiring story from hospital corridors, but rather from the movie “Field of Dreams”, in which Kevin Costner plays a farmer from Iowa, who hears this sentence over and over again when working in his cornfield, calling him to build a baseball field. “The meaning of this is: ‘You start, then people will join and it will grow,'” explains Markel in an interview from his office in the Davidoff Center, where from the window behind him, strangely enough, a statue of Spider-Man standing on the roof of Schneider Hospital can be seen. His determination and vision were always there, and they turned him into a phenom.

    Here is a quick summary of the 44-year-old Markel’s remarkable success to date: At the age of 26, he completed a doctorate in immunology with top honors and within four years he was appointed as the chief scientist of The Ella Institute for Treatment and Research of Melanoma at the Sheba Medical Center. At the age of 35 he became the youngest ever professor at the Faculty of Medicine of Tel Aviv University (and later also completed a master’s degree in business administration). In the same year, he also made an impressive exit, when the German pharmaceutical giant Merck purchased a breakthrough antibody he had developed to eradicate various types of cancer, for $95 million upfront and another $510 million in milestone payments.

    Today, six years later, Markel is already the Deputy Director General of the Rabin Medical Center, Director of the Davidoff Cancer Center, and these days he’s unveiling a new baby, the Samueli Integrative Cancer Pioneering Institute, which merges a biotech incubator with a university research institute and boasts a business culture and key performance indicators (KPIs).

    The institute was established thanks to a donation of around $33 million, raised by Markel from the Samueli Foundation, founded by Dr. Henry Samueli, founder and chairman of the chip giant Broadcom, and his wife Dr. Susan Samueli. This is an unusual donation, not only in scope, but also in its essence. In complete contrast from the typical philanthropy in the public health system, which is often dedicated to the purchase of equipment or the construction of a building, on which the donor’s name is emblazoned, the Samueli Foundation’s contribution is a kind of particularly generous research grant, which is not time-bound. “It will be an organization similar to a startup,” explains Markel, “and the intention is to succeed in creating, through some of our activities, intellectual assets, services, and agreements that will enable the future existence of the institute, and not rely only on additional donations.”

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleSix Norwegian companies leading the country’s biotech scene
    Next Article Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC
    yourbiotech
    • Website

    Related Posts

    Ironwood Enters into Definitive Agreement to Acquire VectivBio, a Clinical-Stage Biotech Company Pioneering Novel Treatments for Severe Rare Gastrointestinal Diseases

    May 26, 2023

    India as a Quad-led biomanufacturing hub

    May 25, 2023

    Manappuram Finance, Rossari Biotech shares trade ex-dividend today

    May 24, 2023

    Scottish Biotech ILC Therapeutics Signs R&D Partnership With Dechra Pharmaceuticals PLC

    May 23, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.